Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03493464 · ClinicalTrials.gov registry record · Phase 2
BR55 in Characterization of Ovarian Lesions
A Phase 2 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03493464 is a Phase 2 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 14 participants.
The verdict
NCT03493464, a Phase 2 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is an exploratory phase II, single center, open label, prospective study of BR55 CEUS for characterization of ovarian lesions in subjects with suspected ovarian cancer.
Interventions
- DRUG BR55
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-12-13 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03493464
The ClinicalTrials.gov registry entry for NCT03493464 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BR55 is the first listed.
NCT03493464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03493464 about?
NCT03493464 is a clinical study titled "BR55 in Characterization of Ovarian Lesions". This is an exploratory phase II, single center, open label, prospective study of BR55 CEUS for characterization of ovarian lesions in subjects with suspected ovarian cancer.
What is the current status of trial NCT03493464?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2018-12-13. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT03493464?
The interventions under investigation include: BR55 (DRUG).
Who is sponsoring clinical trial NCT03493464?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.